Immune Reconstitution in Chronic Lymphocytic Leukemia-Reference-Cited by-同舟云学术

Immune Reconstitution in Chronic Lymphocytic Leukemia

Published:2012-01-10 Issue:1 Volume:7 Page:13-20
ISSN:1558-8211
Container-title:Current Hematologic Malignancy Reports
language:en
Short-container-title:Curr Hematol Malig Rep

Author:

Riches John C.,Ramsay Alan G.,Gribben John G.

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Hematology

Link

http://link.springer.com/content/pdf/10.1007/s11899-011-0106-x.pdf

Reference79 articles.

1. • Eichhorst BF, Busch R, Stilgenbauer S, et al.: First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia. Blood 2009, 114:3382–91. This important clinical trial highlights the challenges of successfully treating elderly patients with CLL, emphasizing the need for novel noncytotoxic therapies for this disease.

2. •• Hallek M, Fischer K, Fingerle-Rowson G, et al.: Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010, 376:1164–74. This phase 3 trial demonstrates the survival advantage of the addition of rituximab to fludarabine and cyclophosphamide, and underpins the current standard of care in CLL.

3. Dunn GP, Bruce AT, Ikeda H, et al. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002;3:991–8.

4. Catovsky D, Miliani E, Okos A, et al. Clinical significance of T-cells in chronic lymphocytic leukaemia. Lancet. 1974;2:751–2.

5. Platsoucas CD, Galinski M, Kempin S, et al. Abnormal T lymphocyte subpopulations in patients with B cell chronic lymphocytic leukemia: an analysis by monoclonal antibodies. J Immunol. 1982;129:2305–12.

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advancing CAR T-cell therapy for chronic lymphocytic leukemia: exploring resistance mechanisms and the innovative strategies to overcome them;Cancer Drug Resistance;2024-05-14

2. Differential Expression of LMNA/C and Insulin Receptor Transcript Variants in Peripheral Blood Mononuclear Cells of Leukemia Patients;Journal of Clinical Medicine;2024-04-27

3. Transforming CLL management with immunotherapy: Investigating the potential of CAR T-cells and bispecific antibodies;Seminars in Hematology;2024-04

4. Theranostic Potentials of Gold Nanomaterials in Hematological Malignancies;Cancers;2022-06-21

5. Biology and Treatment Advances in Cutaneous Squamous Cell Carcinoma;Cancers;2021-11-11